ClinicalTrials.gg
CompletedNCT00667719Updated Jun 7, 2021Results posted

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

A Phase 3 interventional study of Aliskiren and Amlodipine in Essential Hypertension, sponsored by Novartis. Completed at 8 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-07.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
564
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Enrollment
7th of 34
564 · median 314
Started
2008
the only one that year
Phase 3
18 of 34
none open now
Registered
5th of 34
by date
Lead sponsor
3 of 34
Novartis

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 18 in phase 3, and was the 5th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Essential hypertension
  • High blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients 18 years of age or older
  • Male or female participants are eligible.
  • Mean sitting diastolic blood pressure (msDBP) and mean sitting systolic blood pressure (msSBP) Requirements:

    • For newly diagnosed/untreated participants, msDBP ≥ 100 and \< 120 millimeters of mercury (mmHg), and/or msSBP ≥ 160 and \< 200 mmHg at Visit 1 and Visit 2.
    • For previously treated participants, msDBP ≥ 100 and \< 120 mmHg, and/or msSBP ≥ 160 and \< 200 mmHg at Visit 2, Visit 3, or Visit 4.
  • For participants requiring tapering off their previous antihypertensive medication, they must meet the above criteria and completely discontinue all antihypertensive treatment prior to entering the treatment phase of the study.
  • Participants who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written ).

Exclusion criteria

Exclusion Criteria:

  • Inability to discontinue all prior antihypertensive medications safely for a period of 1 week to 4 weeks as required by the protocol.
  • Participants on three antihypertensive drugs with msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg at Visit 1.
  • Participants on four or more antihypertensive drugs at Visit 1.
  • Participants with an msSBP ≥ 200 and msDBP ≥ 120 mmHg anytime during the of the study Visit 1-4 must be discontinued from the study.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (>= 5 milli-international units per milliliter mIU/mL).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
564 participants (actual)

Study arms

  • Experimental
    Aliskiren/Amlodipine/Hydrochlorothiazide

    Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.

    Drug: Aliskiren · Drug: Amlodipine · Drug: Hydrochlorothiazide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death

    An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: 54 weeks

Secondary outcomes

  1. Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

    Time frame: Baseline, Weeks 28 and 54 endpoint

  2. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

    Time frame: Baseline, Weeks 28 and 54 endpoints

  3. Percentage of Participants Achieving the Blood Pressure Control Target of <140/90 mmHg

    Blood pressure control was defined as having a mean sitting diastolic blood pressure \<90 mmHg and a mean sitting systolic blood pressure \<140 mmHg. Percentage of participants achieving the blood pressure control of \< 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28.

    Time frame: Weeks 28 and 54 endpoints

  4. Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure

    Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure \<90 mmHg or a \>=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

    Time frame: Weeks 28 and 54 endpoints

  5. Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Systolic Blood Pressure

    Systolic blood pressure response was defined as a mean sitting systolic blood pressure \<140 mmHg or a \>=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

    Time frame: Weeks 28 and 54 endpoints

07

Results

Posted Jun 7, 2021

Participant flow

Participants with essential hypertension were enrolled in the study at 82 investigative sites worldwide from 5 June 2008 to 5 October 2009.

Participant flow — Overall Study
MilestoneAliskiren /Amlodipine/Hydrochlorothiazide
Started564
Completed493
Not completed71
Withdrew: Adverse event39
Withdrew: Abnormal test procedure1
Withdrew: Unsatisfactory therapeutic effect3
Withdrew: Protocol violation3
Withdrew: Withdrawal by subject17
Withdrew: Lost to follow-up8

Outcome measures

PrimaryNumber of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death

An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
54 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death
ParticipantsAliskiren/Hydrochlorothiazide 300/12.5 mgAliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mgAliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg
Any Adverse Events5754255
Serious Adverse Events0114
Death000
SecondaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

Time frame:
Baseline, Weeks 28 and 54 endpoint
Reported as:
Mean · mmHg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
mmHgAliskiren/Amlodipine/Hydrochlorothiazide
Baseline101.8 ± 7.74
Change from Baseline to Week 28 Endpoint-20.3 ± 8.92
Change from Baseline to Week 54 Endpoint-21.8 ± 8.66
SecondaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

Time frame:
Baseline, Weeks 28 and 54 endpoints
Reported as:
Mean · millimeters of mercury
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
millimeters of mercuryAliskiren/Amlodipine/Hydrochlorothiazide
Baseline166.1 ± 11.59
Change from baseline to Week 28 Endpoint-34.2 ± 14.16
Change from Baseline to Week 54 Endpoint-37.3 ± 14.63
SecondaryPercentage of Participants Achieving the Blood Pressure Control Target of <140/90 mmHg

Blood pressure control was defined as having a mean sitting diastolic blood pressure \<90 mmHg and a mean sitting systolic blood pressure \<140 mmHg. Percentage of participants achieving the blood pressure control of \< 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28.

Time frame:
Weeks 28 and 54 endpoints
Reported as:
Number · percentage of participants
Percentage of Participants Achieving the Blood Pressure Control Target of <140/90 mmHg
percentage of participantsAliskiren/Amlodipine/Hydrochlorothiazide
Week 28 Endpoint69.1
Week 54 Endpoint77.1
SecondaryPercentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure

Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure \<90 mmHg or a \>=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

Time frame:
Weeks 28 and 54 endpoints
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure
percentage of participantsAliskiren/Amlodipine/Hydrochlorothiazide
Week 28 Endpoint91.8
Week 54 Endpoint96.6
SecondaryPercentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Systolic Blood Pressure

Systolic blood pressure response was defined as a mean sitting systolic blood pressure \<140 mmHg or a \>=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.

Time frame:
Weeks 28 and 54 endpoints
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Systolic Blood Pressure
percentage of participantsAliskiren/Amlodipine/Hydrochlorothiazide
Week 28 Endpoint90.2
Week 54 Endpoint93.7

Adverse events

Collected over From Baseline up to 54 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren/Hydrochlorothiazide 300/12.5 mg0/564 (0%)0/564 (0%)21/564 (3.7%)
Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg0/561 (0%)1/561 (0.2%)14/561 (2.5%)
Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg0/556 (0%)14/556 (2.5%)141/556 (25.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventAliskiren/Hydrochlorothiazide 300/12.5 mgAliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mgAliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg
PalpitationsCardiac disorders0/5640/5612/556
ThrombocytopeniaBlood and lymphatic system disorders0/5640/5611/556
Atrial fibrillationCardiac disorders0/5640/5611/556
Inguinal hernia, obstructiveGastrointestinal disorders0/5640/5611/556
Non-cardiac chest painGeneral disorders0/5640/5611/556
BronchitisInfections and infestations0/5640/5611/556
SinusitisInfections and infestations0/5640/5611/556
ArthritisMusculoskeletal and connective tissue disorders0/5640/5611/556
Cervical spinal stenosisMusculoskeletal and connective tissue disorders0/5640/5611/556
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/5640/5611/556
Most frequent other events
Most frequent other events
EventAliskiren/Hydrochlorothiazide 300/12.5 mgAliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mgAliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg
Oedema peripheralGeneral disorders1/5640/56152/556
NasopharyngitisInfections and infestations3/5642/56120/556
BronchitisInfections and infestations2/5643/56116/556
InfluenzaInfections and infestations0/5640/56115/556
HeadacheNervous system disorders10/5646/56115/556
Back painMusculoskeletal and connective tissue disorders0/5642/56112/556
DiarrhoeaGastrointestinal disorders5/5641/56111/556

Baseline characteristics

Treated Population consisted of all participants who received at least one dose of trial medication.

Age, Continuous
Age, Continuous(years)Aliskiren /Amlodipine/Hydrochlorothiazide
Mean55.9 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren /Amlodipine/Hydrochlorothiazide
Female238
Male326
08

Study locations

8 sites
  • Investigative Site
    Houston, Texas, United States
  • Investigative Site
    Belgium, Belgium
  • Investigative Site
    Egypt, Egypt
  • Investigative Site
    Germany, Germany
  • Investigative Site
    Poland, Poland
  • Investigative Site
    Slovakia, Slovakia
  • Investigative Site
    Spain, Spain
  • Investigative Site
    Turkey, Turkey
09

References and documents

Publications

  • Murray AV, Koenig W, Garcia-Puig J, Patel S, Uddin A, Zhang J. Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. J Clin Hypertens (Greenwich). 2012 Dec;14(12):821-7. doi: 10.1111/j.1751-7176.2012.00706.x. Epub 2012 Aug 28. PubMed 23205748 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2008 to primary completion in Oct 2009, 16 months.

Results were first posted in Jun 2021, 11 years 8 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 16 months is close to that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2008
First posted
Apr 28, 2008
StartActual
Jun 5, 2008
Primary completionActual
Oct 5, 2009
CompletionActual
Oct 5, 2009
Results first posted
Jun 7, 2021
Last update
Jun 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00667719
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Apr 28, 2008
Start date
Jun 5, 2008
Primary completion
Oct 5, 2009
Completion
Oct 5, 2009
Results posted
Jun 7, 2021
Last update
Jun 7, 2021

Study contacts

Novartis
study chair · Novartis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Amlodipine · Hydrochlorothiazide

Start the discussion